Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.94)
# 750
Out of 4,944 analysts
141
Total ratings
54.46%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $10.06 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $19.99 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $561.55 | +51.37% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $0.66 | +2,624.80% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.72 | +3,388.37% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.60 | +246.15% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $8.02 | +323.94% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $135.19 | +141.88% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $2.66 | +1,027.82% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $10.60 | +5,258.49% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $395.92 | -29.03% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.30 | +142.42% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.13 | +8,572.57% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $289.33 | +1.96% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $120.14 | -28.42% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $27.87 | +72.23% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.35 | +308.16% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $36.61 | +96.67% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.28 | +290.63% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $85.85 | +16.48% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $191.15 | +5.15% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $48.17 | +76.46% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $12.01 | +166.44% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $20.40 | +963.73% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $20.74 | +131.49% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $15.19 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $432.52 | -64.39% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $58.30 | +98.97% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $5.30 | +1,900.00% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $11.00 | +154.55% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $206.92 | -60.37% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $309.72 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.20 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.06
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.99
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $561.55
Upside: +51.37%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.66
Upside: +2,624.80%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.72
Upside: +3,388.37%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.60
Upside: +246.15%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $8.02
Upside: +323.94%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $135.19
Upside: +141.88%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $2.66
Upside: +1,027.82%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $10.60
Upside: +5,258.49%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $395.92
Upside: -29.03%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $3.30
Upside: +142.42%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.13
Upside: +8,572.57%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $289.33
Upside: +1.96%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $120.14
Upside: -28.42%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $27.87
Upside: +72.23%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $7.35
Upside: +308.16%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $36.61
Upside: +96.67%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.28
Upside: +290.63%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $85.85
Upside: +16.48%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $191.15
Upside: +5.15%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $48.17
Upside: +76.46%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $12.01
Upside: +166.44%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $20.40
Upside: +963.73%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $20.74
Upside: +131.49%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $15.19
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $432.52
Upside: -64.39%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $58.30
Upside: +98.97%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $5.30
Upside: +1,900.00%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $11.00
Upside: +154.55%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $206.92
Upside: -60.37%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $309.72
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.20
Upside: -